卡培他滨市场 - 增长、趋势、COVID-19 影响和预测(2022 - 2027 年)

市场按适应症(乳腺癌、结直肠癌、胃癌等)、分销渠道和地理位置进行细分

市场快照

CAGR
Study Period: 2018 - 2026
Base Year: 2021
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: 5.5 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

市场概况

由于对靶向药物治疗的需求不断增加,以减少可能的副作用而不影响正常细胞,预计研究的卡培他滨市场在预测期内将以 5.5% 的复合年增长率增长。对卡培他滨的需求增加可归因于它们的抗代谢活性,该活性通过干扰 DNA 合成最大限度地减少严重的副作用而发挥作用。此外,被诊断患有癌症和肿瘤的患者日益增加的全球负担可能会推动市场。根据世界卫生组织的报告,癌症是全球死亡的主要原因,估计 2018 年有近 960 万人死亡。此外,估计有 627,000 名女性死于乳腺癌,约占全球女性癌症死亡人数的 15%全球。此外,医疗保健支出急剧增加,正在进行的癌症治疗研发活动可能会为市场提供新的机会。此外,政府和私人组织(如 Cancer Care、Cancer Research UK 和 Cancer Suraksha 计划)日益提高的意识计划预计将在此期间推动全球卡培他滨市场的增长。

报告范围

卡培他滨是一种核苷代谢抑制剂,用作前药。该分子转化为氟尿嘧啶并抑制 DNA 合成,从而减少癌细胞的进展。它是口服给药并被批准用于治疗各种癌症转移性结直肠癌、乳腺癌等。

Indication
Colorectal Cancer
Breast Cancer
Others
Distribution Channel
Hospitals
Clinical Laboratories
Others
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle-East and Africa
GCC
South Africa
Rest of Middle-East and Africa
South America
Brazil
Argentina
Rest of South America

Report scope can be customized per your requirements. Click here.

主要市场趋势

按适应症划分的乳腺癌有望在全球卡培他滨市场占有最大的市场份额

预计乳腺癌细分市场将占最大份额。优势可归因于该药物作为黄金标准的处方增加,因为它们在治疗乳腺癌方面的有效性已得到证实。此外,它们的优势,例如增加获取途径和口服剂量形式的可用性,增强了患者的便利性。此外,在联合治疗中增加卡培他滨处方以及多西他赛、帕妥珠单抗和曲妥珠单抗以延长转移性乳腺癌的总体生存期,进一步推动了预测期内该细分市场的增长。

img

北美在市场上占主导地位,预计在预测期内也会如此。

预计北美将在整个预测期内主导整个卡培他滨市场。占主导地位的原因是该地区各种癌症的流行率上升,如结直肠癌、结肠癌。癌症发病率的增加可能是由于缺乏运动、肥胖、压力和久坐不动的生活方式等多种因素造成的。此外,由于在预测期内美国婴儿潮一代的存在,老年人口的急剧增加导致该地区的收入增加。

例如,根据 2019 年国际糖尿病联盟的数据,北美约有 4800 万成年人患有糖尿病,其中一半以上的患者年龄在 65 岁以上,预计未来还会继续存在。根据美国癌症协会的报告,2017 年美国约有 135,430 例新病例和 50,260 例死于结肠癌和直肠癌

因此,美国庞大的目标人群和增加的可支配收入推动了市场。此外,罗氏、梯瓦和其他进行癌症临床试验的主要参与者的存在预计将有助于在全球卡培他滨市场获得可观的收入份额。

Capecitabine

竞争格局

全球卡培他滨市场竞争适度,由几个主要参与者组成。目前主导市场的知名企业中很少有人采用各种策略,例如收购产品或其他公司以巩固其在全球的市场地位,而其他公司则推出通用产品。例如,2019 年 4 月,Armas Pharmaceuticals, Inc 推出了罗氏 (Roches) 的卡培他滨产品 Xeloda 的仿制药版本。预计此类产品的推出将推动市场增长。目前主导市场的一些公司包括 Cipla Inc.、Teva Pharmaceuticals USA Inc.、F. Hoffmann-La Roche AG (Genentech, Inc.)、Mylan NV 和 Hikma Pharmaceuticals PLC。

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Rising Government Initiatives to Control Growing Global Cancer Burden

      2. 4.2.2 Increasing Incidence of Cancers Around the World

    3. 4.3 Market Restraints

      1. 4.3.1 Highly Expensive Products and Treatment

      2. 4.3.2 Rising Adoption of Substitutes like Raltitrexed, Irinotecan and Leucovorin for Adjuvant Therapy

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 Indication

      1. 5.1.1 Colorectal Cancer

      2. 5.1.2 Breast Cancer

      3. 5.1.3 Others

    2. 5.2 Distribution Channel

      1. 5.2.1 Hospitals

      2. 5.2.2 Clinical Laboratories

      3. 5.2.3 Others

    3. 5.3 Geography

      1. 5.3.1 North America

        1. 5.3.1.1 United States

        2. 5.3.1.2 Canada

        3. 5.3.1.3 Mexico

      2. 5.3.2 Europe

        1. 5.3.2.1 Germany

        2. 5.3.2.2 United Kingdom

        3. 5.3.2.3 France

        4. 5.3.2.4 Italy

        5. 5.3.2.5 Spain

        6. 5.3.2.6 Rest of Europe

      3. 5.3.3 Asia-Pacific

        1. 5.3.3.1 China

        2. 5.3.3.2 Japan

        3. 5.3.3.3 India

        4. 5.3.3.4 Australia

        5. 5.3.3.5 South Korea

        6. 5.3.3.6 Rest of Asia-Pacific

      4. 5.3.4 Middle-East and Africa

        1. 5.3.4.1 GCC

        2. 5.3.4.2 South Africa

        3. 5.3.4.3 Rest of Middle-East and Africa

      5. 5.3.5 South America

        1. 5.3.5.1 Brazil

        2. 5.3.5.2 Argentina

        3. 5.3.5.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 Teva Pharmaceuticals, Inc.

      2. 6.1.2 F. Hoffmann-La Roche AG (Genentech, Inc.)

      3. 6.1.3 Mylan N.V.

      4. 6.1.4 Hikma Pharmaceuticals PLC

      5. 6.1.5 Cipla Inc.

      6. 6.1.6 Dr. Reddy's Laboratories Ltd.

      7. 6.1.7 Fresenius SE & Co. KGaA

      8. 6.1.8 Intas Pharmaceuticals Limited

      9. 6.1.9 Sun Pharmaceutical Industries Limited

      10. 6.1.10 Armas Pharmaceuticals, Inc

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Capecitabine Market market is studied from 2018 - 2026.

The Capecitabine Market is growing at a CAGR of 5.5% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2021.

Teva Pharmaceuticals, Inc, F. Hoffmann-La Roche AG (Genentech, Inc.), Mylan N.V., Hikma Pharmaceuticals PLC, Cipla Inc. are the major companies operating in Capecitabine Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!